Study eligibility criteria
Study appraisal and synthesis methods
Publication stageIn Press Journal Pre-Proof
The authors report no conflict of interest
The study has no funding
PROSPERO n. CRD42022365327
Fetal demise occurs mostly in the third trimester, shortly after the SARS-CoV-2 infection and with histological anomalies associated with transplacental transmission and placental insufficiency.
AJOG AT A GLANCE
A. Why was this study conducted? Because it was unknown if fetal demises (miscarriage or stillbirth) were associated with clinical severity, placental lesions or malformations and if they might be due to actual SARS-CoV-2 fetal infections.
B. What are the key findings? Fetal demises generally occurred 6-13 days after the infection and diagnosed at or right after the delivery (between 14- and 39-weeks’ gestation), without link with maternal clinical severity and comorbidities or with congenital fetal malformations. Most placentas were SARS-CoV-2-positive or presented the histological anomalies previously observed in transplacentally transmitted infections and eventually causing placental insufficiency; ≈65% of the fetuses had a confirmed or possible in utero transmitted infection.
C. What does this study add to what is already known? We synthesize the characteristics of fetal demises from women infected by SARS-CoV-2 and help understand the role of this infection in fetal demise.